Literature DB >> 23784739

Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential.

Edward M Sellers1, Peter J Perrino, Salvatore V Colucci, Stephen C Harris.   

Abstract

Reformulated OxyContin® (oxycodone HCl controlled-release or ORF) was developed as a tamper and abuse-deterrent product, to reduce the risk of product abuse, misuse and their consequences. This noninterventional single-session study asked participants who were medically-healthy recreational opioid users, aged 18 years and older, to consider how they would use commonly available supplies to tamper with placebo ORF and placebo original OxyContin (OC) tablets, and how they would assess the attractiveness of tampering and abusing ORF tablets, as compared with other opioid formulations. Participants provided information on past opioid use, and they assessed the properties of five nonhypothetical oxycodone products and two hypothetical oxycodone products. Participants provided feedback on tampering preferences, preferred tamper methods for each product, overall tampering potential and product preferences. We had 30 participants (27 males and 3 females; mean age 35 years, range 18-51) complete both the interview and tampering sessions. Participants judged OC as the most attractive, valuable, desirable and most likely to be tampered with, from among all opioid products studied. By contrast, they rated ORF as the least attractive, least valuable, least desirable, and least likely to be tampered with among all the nonhypothetical opioid products studied. These results suggested that recreational drug abusers view ORF tablets as tamper-deterrent products.

Entities:  

Keywords:  Addiction; OxyContin; analgesics; drug administration routes; drug reformulation; opiate addiction; opiate dependence; opioid analgesics; oxycodone; prescription drug abuse; tamper resistant drugs

Mesh:

Substances:

Year:  2013        PMID: 23784739     DOI: 10.1177/0269881113493364

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  6 in total

1.  Risk based in vitro performance assessment of extended release abuse deterrent formulations.

Authors:  Xiaoming Xu; Abhay Gupta; Manar Al-Ghabeish; Silvia N Calderon; Mansoor A Khan
Journal:  Int J Pharm       Date:  2016-01-16       Impact factor: 5.875

2.  In response to Gudin et al. - Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties.

Authors:  Nancy T Crudele; Jennifer Giordano; Ram P Kapil; Amarita S Randhawa
Journal:  Pain Med       Date:  2017-05-01       Impact factor: 3.750

Review 3.  An overview of abuse-deterrent opioids and recommendations for practical patient care.

Authors:  Jeremy A Adler; Theresa Mallick-Searle
Journal:  J Multidiscip Healthc       Date:  2018-07-11

4.  Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation.

Authors:  Nelson E Sessler; Jerod M Downing; Hrishikesh Kale; Howard D Chilcoat; Todd F Baumgartner; Paul M Coplan
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-06-11       Impact factor: 2.890

5.  Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.

Authors:  Stephen C Harris; Alessandra Cipriano; Salvatore V Colucci; Ram P Kapil; Pierre Geoffroy; Talar Hopyan; Naama Levy-Cooperman
Journal:  Pain Med       Date:  2015-12-14       Impact factor: 3.750

6.  How Resistant to Tampering are Codeine Containing Analgesics on the Market? Assessing the Potential for Opioid Extraction.

Authors:  Andreas Kimergård; Paolo Deluca; Peter Hindersson; Torben Breindahl
Journal:  Pain Ther       Date:  2016-06-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.